| 摘要 |
<p>The present invention provided a compound of the formula: <CHEM> or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: A is a group of the formula (IA) or (IB): <CHEM> R<1> is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R<2> is hydrogen or C1-4alkyl; R<3> and R<4> are the same or different and are a variety of substituents X is alkanediyl containing 1-6 carbon atoms optionally interrupted by O, S(O)x (wherein x is zero, one or two), -CONR<5>- or -NR<5>- wherein R<5> is hydrogen or C1-4alkyl; or X is alkenediyl containing 2-6 carbon atoms optionally interrupted by O, S(O)x or -NR<5>- wherein x and R<5> are as hereinbefore defined; with the provisos that: i) the interrupting function (O,S(O)x,NR<5>,-CONR<5>-) may be directly linked to the ring A, but is not directly linked to the -COOH function or to any carbon-carbon double bond in X; and (ii) when the interrupting function is -SO- or -SO2- it is not beta to the COOH function or delta if there is an intervening carbon-carbon double bond in X.</p> |
